Skip to main content

Structure Therapeutics

Structure Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on developing orally available small molecule therapeutics for metabolic and pulmonary diseases. The company utilizes its proprietary structure-based drug discovery platform to engineer oral G-protein coupled receptor therapeutics, including lead candidate GSBR-1290, an oral GLP-1 receptor agonist for obesity and type 2 diabetes. Main revenue drivers currently stem from investment capital financing, research collaborations, and potential development milestones as clinical trials progress. Structure Therapeutics targets endocrinologists, clinical research networks, biopharmaceutical partners, and metabolic disease patients in North America and global markets. The company holds an innovative position in oral small molecule GLP-1 and GPCR drug discovery. Headquartered in South San Francisco, California, it is listed on the Nasdaq Stock Market.

5 of the funds FundTelligence covers report a position in Structure Therapeutics.

Legal name
Structure Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
5
Exposure themes
Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health

Funds holding Structure Therapeutics

Loading...